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Abstract An individual’s immune response is critical for
host protection from many different pathogens, and the
responsiveness can be assessed by the amount of cytokine
production upon stimulating bacterial components such as
lipopolysaccharide (LPS). The difference between individuals in
their peripheral blood mononuclear cells (PBMC) responsiveness
to LPS, a Gram-negative endotoxin, was investigated from 27
healthy individuals. We observed a large variation in IFNγ
production among different individuals. The PBMC of the
consistently three highest and three lowest IFNγ producers
were investigated. Since previous studies described that a
single point mutation in the coding region of TLR2 and TLR4
is linked to the individual responsiveness to pathogenic bacterial
infections, we first examined the known point mutations in
the coding region of TLR2
Pro681His
, TLR4
Pro714His
 located in the
cytoplasmic regions of the Toll-like domain as well as TLR4
Asp299Gly
located in the extracellular region. None of these mutations were
associated with an individual’s responsiveness to LPS, despite
the presence of TLR4
Asp299Gly
 mutation. Further investigation
revealed that the variation of PBMC responsiveness to LPS
among healthy individuals was due to constitutive expression
levels of TLR4 and TLR2. This result is consistent with an
aging-related low expression of Toll-like receptors in the mouse
model of LPS responsiveness. The present study therefore
suggests that the constitutive expression levels of TLR2 and
TLR4 may contribute to the individual response to LPS.
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Toll-like receptors (TLR) were first identified in Drosophila.
Soon after, mammalian homologs were characterized as
mediators of the immune response to microbial ligands
[21, 37]. Although CD14 has been recognized as a co-
receptor for lipopolysaccharide (LPS) [30], TLR2-9 have
also been identified for the receptors of microbial and
pharmaceutical products [1, 2, 8]. TLRs are pattern recognition
molecules and it has been suggested that TLR can
discriminate between Gram-negative and Gram-positive
organisms [31]. Gram-positive bacteria and yeast cell wall
components are ligands for TLR1, 2, and 6, whereas the
predominant Gram-negative bacterial product LPS is a
ligand for TLR4. Recent data examining LPS responses in
TLR2-deficient mice indicate that TLR2 is not required for
LPS signaling when TLR4 is present [7, 29, 31]. Numerous
reports have indicated that LPS is not a ligand for TLR2,
the TLR2-stimulating activity of commercial LPS being
due to the presence of contamination with other microbial
components triggering TLR2 signaling [9].
Upon stimulating TLRs, there is the recruitment of
adaptor molecules in the cytoplasm, such as MyD88 [8, 12,
13] and Toll/IL-1R domain-containing adaptor protein
(Triap) [4, 10] consequently activating IL-1R-associated
kinases (IRAKs) by phosphorylation. Then, IRAK downstream
signaling molecules activate tumor necrosis factor receptor
associated factor-6 (TRAF-6) [20, 38], transforming growth
factor-β-activated kinase-1 (TAK1) [19], I-κB kinase, I-κB
degradation, and finally NF-κB nuclear translocation,
respectively. Bacterial components including LPS induce
various cytokine productions in mouse macrophage cells
mainly through the NF-κB signal pathway [14, 18]. The
measurement of cytokine productions is the easiest assessment
for cell responsiveness, which is used for different in vitro
models [15, 17, 28].
A point mutation within mice TLR4
Pro712His
 [24] and
TLR2
Pro681His
 [31] underlines the bacterial pathogen
hyporesponsiveness. Although there has not been reported a
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point mutation within human TLR4 and TLR2 in the Toll-
like domain structural basis of human, TLR2 and TLR4
explain an importance of those residues for interacting
with downstream signaling molecules [36]. However,
recently, a point mutation in the extracellular domain of
TLR4
Asp299Gly
 has been suggested to be responsible for the
hyporesponsiveness of healthy individuals after LPS
stimulation [23].
Although the variability of LPS responsiveness in many
mice models has been identified by a positional cloning
with a particular inbred strain of mice, little is known about
the variability of LPS responsiveness in individuals except
for a point mutation in the extracelluar domain of TLR4,
which may be a unique case. Thus, it is possible that a
common causative factor may exist for the variability of
LPS responsiveness in healthy individuals. In the present
study, we demonstrate that the constitutive expression rates
of TLR4 and TLR2 influence the variability of LPS
responsiveness in healthy individuals.
MATERIALS AND METHODS
Reagents
Histopaque, LPS, and Tri-Reagent were obtained from
Sigma (St. Louis, MO, U.S.A.). The PCR purification kit was
purchased from QIAGEN (Valencia, CA, U.S.A.). Superscript
II RT and DNA Taq polymerase were purchased from
Invitrogen (Carlsbad, CA, U.S.A.). IL-12 was obtained
from Peprotech (Rocky Hill, NJ, U.S.A.). The liquid-phase
electrochemiluminescence (ECL) reagents were obtained
from Bioveris (Gaithersburg, MD, U.S.A.).
Cytokine Assays
PBMC were isolated from healthy donors using Histopaque
(Sigma). The combined Colorado Investigational Review
Board approved the study. PBMC (1.5×10
7
) were seeded
in 96-well plates in 0.2 ml of RPMI containing 10% FCS.
Cells were then stimulated with LPS (Sigma), phenol-
extracted LPS (pLPS, excluding TLR2 activation was
prepared as described before [26]), or IL-12 (Peprotech)
plus IL-18, which was produced as described [16]. The
plates were placed in a cell culture incubator for 24 h. The
culture supernatant was collected for human IFNγ and IL-
10 measurements. The liquid-phase ECL method was used
to measure different cytokines in cell culture media
(Bioveris). The amount of electrochemiluminescence was
determined using an Origen Analyzer (Bioveris).
RT-PCR
Total RNA was isolated with Tri-Reagent (Sigma) from
freshly isolated PBMC. Superscript II RT (Invitrogen)
converted 2 µg of total RNA to first-strand cDNA and then
the PCR reaction was performed at 94
o
C for 45 sec, 70
o
C
for 2 min, and 59
o
C for 1 min for 30 cycles. A pair of sense
and reverse primers was used for the RT-PCR; for TLR2,
5' TGT GGG TTG AAG CAC TGG ACA (sense) and 5'
CTT AAA TAT GGG AAC CTA GGA C (reverse); for
TLR4, 5' CAC GGA GGT GGT TCC TAA TAT (sense)
and 5' CCT CTT CAG ATA GAT GTT GCT (reverse); for
CD14, 5' GGT TCG GAA GAC TTA TCG ACC (sense)
and 5' ATT CTG TCT TGG ATC TTA GGC (reverse); for
GAPDH, 5' ACC ACA GTC CAT GCCATC AC (sense)
and 5' TCC ACC ACC CTG TTG CTG TA (reverse). The
PCR products were subjected to 1% agarose gel electrophoresis
and photographed.
DNA Sequencing
For DNA sequencing, the PCR products of TLR2 and
TLR4 were amplified with the following sense and reverse
primers for specific regions of the known mutation sites of
both TLR2/TLR4; for TLR2
Pro681His
, AAT GTC ACA GGA
CAG CAC TGG (sense) and 5' GCA GAA GCG CTG
GGG AAT G (reverse); for TLR4
Asp229Gly
, 5' TGG AGA
CAA ATC TAG CAT CTC (sense) and 5' TCA ATA GTC
ACA CTC ACC AGG (reverse); for TLR4
Pro714His
, 5' GTC
TAT AAG TTC TAT TTT CAC C (sense) and 5' TCC
AGC AGG GCT TTT CTG AGT (reverse). These PCR
products were cleaned with a PCR purification kit (QIAGEN)
and then sequenced at the core facility in the University of
Colorado Health Sciences Center. For DNA sequencing,
the following primers were used: for TLR2
Pro681His
, 5' CAG
CAG GAA CAT CTG CTA TGA; for TLR4
Asp229Gly
, 5'
AGA AGT CCA TCG TTT GGT TC; for TLR4
Pro714His
, 5'
ATG AGG ACT GGG TAA GGA ATG.
RESULTS
Individual Variation in the Response to LPS
In order to investigate LPS responsiveness in individuals,
human PBMC were freshly isolated from 27 healthy
volunteers. Among these volunteers, three individuals
were high producers (500 pg/ml) of IFNγ, and three
individuals were low producers (50 pg/ml) of human IFNγ,
whereas 21 volunteers remained between 50 and 500 pg/
ml of IFNγ induction after 24 h by LPS (Fig. 1). Phenol-
extracted LPS (pLPS)-induced IFNγ, excluding TLR2
activation, was similar to LPS-induced IFNγ. In parallel,
PBMC from the same individuals were stimulated with IL-
12 plus IL-18, which directly stimulated T-cells in PBMC.
All 27 individuals showed pronounced induction of IFNγ
compared with LPS or pLPS (Fig. 1). These results
demonstrated that there was no defect in the T-cell
response to IL-12 or IL-18.
We next examined other cytokines produced by three
individuals who showed high response and low response
to LPS, which may postulate an initial observation of
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individual LPS responsiveness by IFNγ induction. The
production of Th2 cytokine IL-10 (Fig. 2B) showed a
contrary result to IFNγ induction (Fig. 2A). IL-10, known
as a suppressor of Th1 cytokines, was highly induced in
individuals with poor responsiveness to LPS in terms of
IFNγ production.
Examination of Single Point Mutation in TLR2 and
TLR4
We investigated whether the variation between high and
low responders was due to the known TLR2 and TLR4
Fig. 1. Variability between individuals in the response to LPS
by IFNγ induction.
Human peripheral blood mononuclear cells (PBMC) were isolated from 27
healthy donors and were stimulated as indicated [LPS (1 µg/ml), pLPS
(1 µg/ml), or IL-12 (1 ng/ml) plus IL-18 (20 ng/ml)]. ECL measured the
IFNγ in PBMC culture supernatant.
Fig. 2. Comparison of the three high or three low responders in cytokine inductions.
(A) LPS or pLPS-induced IFNγ and (B) LPS or pLPS-induced IL-10 in three high or low responders. The graphs represent the mean of the three individuals
of high or the three individuals of low responders from Fig. 1.
Fig. 3. DNA sequence alignment of six individuals, three high
and three low responders.
The sequence alignments data are (A) the sequencing result of the
intracellular domain in the region of amino acid residue Pro681 of TLR2;
(B) extracellular domain in the region of amino acid residue Asp229 of
TLR4; (C) intracellular domain in the region of amino acid residue Pro712
of TLR4. High or low responder is indicated on the right of the figure.
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single point mutation in the cytoplasmic region of the Toll-
like domain. The complete coding regions of TLR2 and
TLR4 RT-PCR products were amplified with a specific
sense and reverse primer in order to examine a possible
point mutation in the Toll-like domain of TLR2 and TLR4.
As shown in Figs. 3A and 3C, both the three high and
three low responders exhibited no mutation in TLR2
Pro681His
or in TLR4
Pro714His
. Although the extracelluar domain of
TLR4
Asp299Gly
 had a point mutation in individuals as shown
in Fig. 3B, there was no correlation between the mutation
and LPS responsiveness in individuals. The DNA sequencing
chromatography result of one high and low responder is
shown in Fig. 4. The two volunteers (26 and 43) had no
mutation as depicted in Fig. 4B, but the other four volunteers
(3, 8, 11, and 14) had a heterozygote point mutation.
Constitutive Steady-State Expression of TLR4 and
TLR2
We further investigated individual LPS responses by
performing semiquantitative RT-PCR for genes directly
related to LPS activity. The total RNA samples from three
high and three low responders were examined for the complete
TLR4 coding region by RT-PCR. The results revealed that
the expression level of TLR4 in the high responders was
consistently greater than the level in low responders (Fig. 5).
Similar differences in the level of TLR2 expression were
also observed between high and low responders. However,
there was no significant difference in the level of CD14
expression between high and low responders (Fig. 5).
DISCUSSION
In the present study, we demonstrate that the variability of
LPS responsiveness among individuals is associated with
differences in the level of constitutive expression of TLR2
and TLR4. TLR4 is a receptor for endotoxin, the glycolipid
present on the outer wall of all Gram-negative bacteria
[7, 31]. Patients with Gram-negative bacterial infection
can exhibit a severe clinical condition called sepsis, which
eventually leads to septic shock with multi-organ failure
and a high mortality. Gram-negative bacterial cell wall is
an important mediator of these symptoms, which is called
endotoxin (LPS). LPS was identified as the main active
component of the Gram-negative bacterial cell wall, which
induces hyperactivation during Gram-negative sepsis, and
its binding protein (LBP) structure was characterized [27].
Arbour et al. [3] reported a single nucleotide A896G
substitution, resulting in replacement of the aspartic acid
residue with glycine at amino acid residue 299 in the
extracelluar domain of human TLR4. They have shown
that a single point mutation of Asp299Gly decreased
LPS-induced NF-κB gel shift by only 25%, which was
compared with wild type in transfected THP-1 cells. Among 74
individuals, 9 were heterozygote and one was homozygote
in this mutation. Although Arbour et al. [3] suggested a cause
of LPS hyperresponsiveness by a single point mutation
Asp299Gly, this finding does not account for the actual
frequency of LPS responsiveness as well as a cause of LPS
hyperresponders. In our study from freshly isolated human
PBMC, the LPS responsiveness variability occurred more
frequently. For example, three of 27 were hyporesponders
and three of 27 were hyperresponders. Contrary to the
result of a single point mutation, our finding of the
variability of LPS responsiveness was tightly correlated to
the level of  theconstitutive expression rate of TLR4, but not
CD14. Soluble or glycosylphosphatidylinositol-anchored
(GPA) membrane-bound CD14 is required for LPS
signaling [35]. Interestingly, TLR2 expression was also
low in individuals low responsive for LPS (Fig. 5).
Fig. 4. DNA chromatography sequencing result of the RT-PCR
product.
A. The wild-type volunteer shows no mutation at amino acid residue
Asp299 in the extracelluar domain of TLR4. The result represents one of
two volunteers. B. The heterozygote volunteer shows a mixed A signal
with R(G/A). The result represents one of four volunteers.
Fig. 5. The examination of TLR4, TLR2, and CD14 expression
by RT-PCR.
The left three lanes are individual high responders to LPS and the next
right three lanes are low responders, as indicated at top of the figure. The
RT-PCR of TLR4 (top), of TLR2 (middle), and of CD14 (bottom) are
shown.
1866 JAEKAL et al.
Certain transcription factors involvement in the promoters
of TLR2 [6, 23, 34] and TLR4 [11, 25] modulate the
expression of TLR2 and TLR4, respectively. It is likely
that the constitutive expression levels of TLRs contribute
to the variability in the response to LPS. TLR2 and TLR4
promoters are distinct in their regulation of each putative
5'-proximal promoter activation without the typical TATA
box. The enhance elements of NF-κB and Sp1 in the 5'
upstream region of the TLR2 gene are necessary for maximal
transcription of murine TLR2 induced by Mycobacterium
avium [34]. However, human TLR2 constitutive expression
is controlled by two Sp1 sites, including the involvement
of a PU1 site within -220 of the transcription initiation site
of the TLR2 promoter [6]. In contrast to TLR2, a PU1 site
in the proximal promoter region of TLR4 [25] tightly
regulates TLR4 constitutive expression. It is possible that
the difference in the constitutive expression levels in TLR4
and TLR2 contributing to individual LPS responsiveness
in PBMC is dictated by PU1 or other transcription factors.
The control of these transcription factors in high and low
LPS responders remains unknown.
Recently, an age-related decline in immune function has
been observed between young (2-3 months) and old (18-
24 months) C57BL/C mice [26], due to the decrease of TLRs
expression and function. In humans, the age-related decline of
immune response is due to a decreasing signal sensitivity
of p38 MAPK rather than the expression level of the Toll-
like receptor [33]. However, the reduction of p38 MAPK
was not significant in that report. This study illustrates the
decline in immune response, which is a hallmark of ageing
in individuals that may be correlated with the effectiveness
of vaccination [5] as well as explain age-related change in
the adaptive immune response [22]. Although the present
study was carried out in healthy male and female volunteers
with ages between 20 and 40 years, our data and Renshaw
et al. [26] consent in the explaining that response to LPS
tightly correlates to the TLRs expression. In addition to
this, Van der Graaf et al. [32] recently described that no
differences in either the production of the proinflammatory
cytokine TNFα or the antiinflammatory cytokine interleukin-
10 were observed between volunteers with the wild-type
allele, volunteers heterozygous for the Asp299Gly allele,
and one volunteer homozygous for the TLR4 variant.
The present study suggests that the constitutive TLRs
gene expression contributes to LPS responsiveness in
individuals. Although our finding and the Renshaw et al.
[26] report are independent investigations, the two studies
comply in that there is a correlation between TLRs gene
expression rate and LPS responsiveness. The low or high
expression rate of TLR2/TLR4 on the cell surface probably
influences the downstream events of LPS signal triggering
an endotoxin response. These data encourage further study
in the regulation of constitutive TLR2 and TLR4 gene
expression correlated to an individual’s LPS responsiveness.
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